News FDA to review Sanofi's Dupixent in asthma The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema.
News Rumours of $1.65bn GSK bid for respiratory partners Vectura GlaxoSmithKline could be poised to acquire its respiratory partner, UK biotech Vectura, for $1.65bn.
News AZ's asthma drug Fasenra approved in EU A further 3,400 children are eligible for treatment with Orkambi
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.